For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual ...
Oric Pharmaceuticals (ORIC) announced focused registrational clinical development plans for its two lead programs, an extension of projected ...
The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression, J&J said in a news release on Tuesday, Jan. 21. The decision came after a ...
New data show that external-beam radiation therapy yielded superior local control and progression-free survival vs TACE in ...
Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...
Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior treatment, according to the TiNivo-2 study.
Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Two PYX-201 trials are now actively recruiting and are designed to evaluate PYX-201 as monotherapy in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC ...
Symptom scores remained stable over time, with similar QOL trends in both treatment arms.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果